Omnicare Advances Court-Supervised Process While Continuing to Deliver Enhanced Value to Customers

Rhea-AI Summary

Omnicare (NYSE: CVS) entered an asset purchase agreement with GenieRx, which will act as the stalking horse bidder in Omnicare's court‑supervised sale process.

The bid establishes a sale floor; competing bids are due April 30, 2026, an auction is expected May 5, 2026, and a court hearing to approve the winning bid will follow. Omnicare says it will continue serving skilled nursing and assisted living customers during the process.

Positive

• Asset purchase agreement executed with GenieRx as stalking horse bidder
• Competing bids deadline set for April 30, 2026
• Auction date scheduled for May 5, 2026
• Company states continued focus on uninterrupted resident pharmacy care

Negative

• Sale subject to higher bids, creating execution uncertainty for the proposed transaction
• Court‑supervised sale indicates Omnicare is undergoing restructuring

News Market Reaction – CVS

+0.93%

1 alert

+0.93% News Effect

On the day this news was published, CVS gained 0.93%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Bid deadline: April 30, 2026 Auction date: May 5, 2026 Toll-free phone: (833) 570-5323 +1 more

4 metrics

Bid deadline April 30, 2026 Deadline for competing bids in Omnicare court-supervised sale

Auction date May 5, 2026 Expected auction date if qualified bids are received

Toll-free phone (833) 570-5323 Stretto contact for Omnicare court proceedings (U.S./Canada)

Intl phone (949) 276-9547 Stretto contact for calls outside U.S. and Canada

Market Reality Check

Price: $73.49 Vol: Volume 6,460,796 vs 20-da...

normal vol

$73.49 Last Close

Volume Volume 6,460,796 vs 20-day average 7,561,265 (relative volume 0.85) indicates no outsized trading reaction. normal

Technical Price 71.82 is below 200-day MA of 74.36 and 15.65% below 52-week high, 23.08% above 52-week low.

Peers on Argus

CVS gained 2.4% with peers also positive: CI +2.62%, ELV +1.95%, HUM +3.45%, CNC...

CVS gained 2.4% with peers also positive: CI +2.62%, ELV +1.95%, HUM +3.45%, CNC +2.14%, MOH +1.26%, suggesting a supportive sector backdrop alongside the Omnicare update.

Historical Context

5 past events · Latest: Mar 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 30	Store expansion	Positive	+0.1%	Opening first pharmacy-only Chicago site, with plans for additional locations.
Mar 18	Dividend declaration	Positive	-1.6%	Quarterly dividend of $0.665 per share with set record and payment dates.
Mar 18	Community investment	Positive	-2.4%	$2.24M Health Zone investment to strengthen community health in Charlotte.
Mar 10	Community investment	Positive	-2.5%	$2.24M Health Zone investment to expand community-based care in Ohio.
Mar 05	Tech partnership	Positive	-2.3%	Strategic Google Cloud partnership to launch Health100 AI engagement platform.

Pattern Detected

Recent generally positive corporate and community news often saw flat or negative next-day moves, indicating limited short-term price responsiveness to such announcements.

Recent Company History

Over the past month, CVS issued several positive updates, including a new pharmacy-only location in Chicago on Mar 30, community health investments of $2.24M in Charlotte and Ohio, a quarterly dividend of $0.665 per share, and a strategic AI-focused partnership with Google Cloud. Despite constructive themes, four of these five items saw negative next-day price moves, suggesting modest or contrarian trading reactions to good news.

Market Pulse Summary

This announcement detailed Omnicare’s progress in a court‑supervised sale, naming GenieRx as stalkin...

Analysis

This announcement detailed Omnicare’s progress in a court‑supervised sale, naming GenieRx as stalking horse bidder and setting an April 30, 2026 bid deadline with a potential May 5, 2026 auction. It emphasized continued service to skilled nursing and assisted living customers through clinical programs and transparent pricing. In context, investors can track execution of these sale milestones and any subsequent updates on Omnicare’s long‑term strategic positioning within CVS.

Key Terms

asset purchase agreement, stalking horse bidder, court-supervised sale process, CMS value‑based purchasing measures, +2 more

6 terms

asset purchase agreement financial

"announced it has entered into an asset purchase agreement with GenieRx Holdings"

An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.

stalking horse bidder financial

"GenieRx will serve as the "stalking horse bidder" in the Company's ongoing"

A stalking horse bidder is a company or investor that makes the first formal purchase offer for assets being sold in a bankruptcy process, setting a baseline price and key terms for a future auction. It matters to investors because that opening bid establishes a floor price and can encourage or deter competing offers, while often including protections that affect how much value creditors and shareholders may recover—think of it as the first bid at an estate sale that sets expectations for everyone else.

court-supervised sale process regulatory

"GenieRx will serve as the "stalking horse bidder" in the Company's ongoing court‑supervised sale process."

A court-supervised sale process is a legally overseen method for selling a company's assets or business, typically used when a company is in financial distress or bankruptcy. Think of it like a legally managed estate sale where a judge and creditors set the rules to ensure assets are sold fairly and transparently; investors care because the process affects how much creditors and shareholders recover, the timeline for payouts, and whether the business continues under new ownership.

CMS value‑based purchasing measures regulatory

"clinical programs aligned with CMS value‑based purchasing measures, and analytics"

CMS value-based purchasing measures are the set of quality, safety, outcome and patient-experience metrics that the U.S. Centers for Medicare & Medicaid Services uses to reward or reduce payments to hospitals and other providers based on how well they perform. For investors, they matter because they directly affect healthcare providers’ revenue and margins—think of it like a performance review that changes a company’s paycheck—so strong or weak scores can alter profitability, regulatory risk and market value.

acos medical

"analytics that support ISNPs, ACOs, and other risk‑bearing care models."

Accountable Care Organizations (ACOs) are groups of doctors, hospitals and other health providers that voluntarily coordinate care for a defined patient population and share responsibility for both quality and total cost. For investors, ACOs matter because they change how healthcare providers earn money — shifting payment toward keeping people healthier and avoiding expensive treatments, which can affect revenue stability, margins and the incentives behind medical spending.

proof of claim regulatory

"including bidding procedures and instructions on how to file a proof of claim"

A proof of claim is a formal document a creditor files in a bankruptcy or insolvency case that states how much a debtor owes and why the debt is valid. It acts like a ballot or ticket to claim a share of the debtor’s remaining assets; whether and how a claim is filed, allowed, or disputed determines if and how much money a creditor or investor may receive, so missed or inaccurate filings can reduce recoveries.

AI-generated analysis. Not financial advice.

Enters into Asset Purchase Agreement with GenieRx

WOONSOCKET, R.I., April 1, 2026 /PRNewswire/ -- Omnicare, LLC (the "Company" or "Omnicare"), a subsidiary of CVS Health (NYSE: CVS), today announced it has entered into an asset purchase agreement with GenieRx Holdings LLC ("GenieRx"), a joint partnership between private investment firm Milrose Capital LLC and health-care investment and management firm Integro Asset Management LLC, which does business as Integro Healthcare Services. GenieRx will serve as the "stalking horse bidder" in the Company's ongoing court‑supervised sale process.

"We are making meaningful progress in our court‑supervised process and are pleased to enter into this purchase agreement with GenieRx," said David Azzolina, President of Omnicare. "GenieRx's interest reflects the strength of Omnicare's clinical expertise, the trust we have earned from the skilled nursing and senior living communities we serve, and the essential role our teams play in supporting high‑quality care for residents. We are grateful for the continued support of our customers and for the dedication of our colleagues, who remain focused every day on serving residents with care and professionalism."

Omnicare continues to focus on helping skilled nursing and assisted living providers navigate the increasing clinical, regulatory, and operational complexity of long‑term care. As the sale process moves forward, the Company remains engaged with skilled nursing facilities through transparent pricing approaches, clinical programs aligned with CMS value‑based purchasing measures, and analytics that support ISNPs, ACOs, and other risk‑bearing care models.

For assisted living communities, Omnicare continues to emphasize a partnership‑driven approach to pharmacy services, programs designed to support rising resident acuity and aging‑in‑place, and ongoing improvements to billing, delivery, and communication experiences for operators and residents.

Throughout the court‑supervised process, Omnicare remains focused on supporting its customers and ensuring residents continue to receive safe, reliable pharmacy care.

Additional Information About the Court-Supervised Sale Process

As part of Omnicare's ongoing court-supervised process, GenieRx will serve as a "stalking horse bidder", whereby the agreement with GenieRx will set the floor for the sale of the Company's assets. Accordingly, the proposed agreement is subject to higher or otherwise better offers from other qualified bidders.

The deadline for interested parties to submit competing bids is April 30, 2026. If qualified bids are received, an auction is expected to be held on May 5, 2026. A hearing to approve the sale to the winning bidder will be scheduled shortly thereafter, subject to the availability of the Court.

Additional information regarding Omnicare's court-supervised process is available at www.OmnicareRestructuring.com.

Court filings and other information related to the proceedings, including bidding procedures and instructions on how to file a proof of claim, are available on a separate website administered by Omnicare's claims agent, Stretto, at https://cases.stretto.com/Omnicare, by calling Stretto representatives toll-free at (833) 570-5323 or (949) 276-9547 for calls originating outside of the U.S. or Canada, or by sending an email to TeamOmnicare@stretto.com.

Advisors

Jenner & Block LLP and Haynes Boone are serving as legal counsel, Houlihan Lokey is serving as investment banker and Alvarez & Marsal is serving as restructuring advisor to Omnicare.

About Omnicare

Omnicare is a national leading provider of pharmacy services to the long-term care market, which includes skilled nursing facilities and independent and assisted living communities, addressing the needs of an aging population across the continuum of senior care.

For more information, visit www.omnicare.com.

About CVS Health

CVS Health® is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media Contacts

Omnicare
Aaron Palash
212-355-4449
OmnicareMedia@joelefrank.com

CVS Health
Ethan Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/omnicare-advances-court-supervised-process-while-continuing-to-deliver-enhanced-value-to-customers-302731896.html

SOURCE CVS Health

FAQ

What did Omnicare (CVS) announce about the GenieRx asset purchase agreement on April 1, 2026?

Omnicare announced it entered an asset purchase agreement with GenieRx, which will serve as the stalking horse bidder. According to the company, the agreement sets a floor price while allowing higher or better offers from other qualified bidders.

What are the key dates for Omnicare's court‑supervised sale process for CVS/Omnicare in April–May 2026?

Competing bidders must submit offers by April 30, 2026, and an auction is expected on May 5, 2026. According to the company, a court hearing to approve the sale will be scheduled shortly after the auction if qualified bids are received.

How does the GenieRx stalking horse bid affect potential buyers of Omnicare (CVS)?

The GenieRx agreement establishes a minimum sale price that other bidders must exceed to win. According to the company, this stalking horse role is intended to set a floor and encourage competitive higher or otherwise better bids during the auction process.

Will Omnicare (CVS) continue serving skilled nursing and assisted living customers during the sale process?

Yes. Omnicare says it will continue providing pharmacy, clinical programs, and operational support to skilled nursing and assisted living providers during the court‑supervised process. According to the company, continuity of resident care remains a primary focus throughout the proceedings.

Where can stakeholders find court filings and claims information for Omnicare's (CVS) sale process?

Court filings and claims instructions are available on the case website administered by Stretto at https://cases.stretto.com/Omnicare. According to the company, additional information is also provided at www.OmnicareRestructuring.com and via Stretto support phone and email.